Cited by 87Ovarian function and disordersReproductive Health and TechnologiesReproductive Biology and Fertility

Aromatase inhibitors in ovulation induction

M.F. Mitwally, Robert F. Casper·2004·Seminars in Reproductive Medicine

Abstract

The new third generation aromatase inhibitors are extremely potent and specific oral inhibitors of estrogen production. We reported the success of using aromatase inhibitors for induction of ovulation in World Health Organization (WHO) type II anovulatory patients. Promising pregnancy rates were associated with the use of aromatase inhibitors for induction of ovulation in these women. In addition, the use of aromatase inhibition in conjunction with gonadotropin injection was associated with a significant reduction in the gonadotropin dose required for optimum controlled ovarian hyperstimulation. We believe that these oral agents are efficient and safe and have many advantages compared with clomiphene citrate (CC). We propose that aromatase inhibitors will replace CC in the future as the new primary treatment for ovulation induction. In this review, we present an update on the use of aromatase inhibitors for induction of ovulation and we discuss several new areas of potential interest regarding the use of aromatase inhibitors, either alone or together with recombinant follicle-stimulating hormone (FSH) for infertility treatment. Further research in these areas may demonstrate an expanded role in assisted reproductive technologies.

Integrity signals

Registry

Crossref · 10.1055/s-2004-823028

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Unlike CC, aromatase inhibitors do not carry an antiestrogenic effect on the endometrium.

    “Unlike CC, they do not carry an antiestrogenic effect on the endometrium.”

    From A new era in ovulation induction (2006) · cites this paper as [47]

  • Blocking E production by inhibiting aromatization releases the hypothalamic-pituitary axis from estrogenic negative feedback, increasing FSH secretion and stimulating the development of ovarian follicles.

    “Mitwally and Casper (47) first postulated that blocking E production by inhibiting aromatization would release the hypothalamic-pituitary axis from estrogenic negative feedback.As a result, FSH secretion increases, stimulating the development of ovarian follicles (Fig. 1).”

    From A new era in ovulation induction (2006) · cites this paper as [47]

  • Androgens that normally convert to estrogens accumulate in the ovary and increase follicular sensitivity to FSH.

    “In addition, androgens that normally converted to estrogens accumulate in the ovary, and these androgens increase follicular sensitivity to FSH (47).”

    From A new era in ovulation induction (2006) · cites this paper as [47]

  • In women with polycystic ovary syndrome (PCOS), the effects of aromatase inhibitors are more prominent because they block high levels of E from androgen conversion.

    “Because aromatase inhibitors block high levels of E from androgen conversion, the effects in women with polycystic ovary syndrome (PCOS) are more prominent (47).”

    From A new era in ovulation induction (2006) · cites this paper as [47]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mitwally, M. F., & Casper, R. F.
Affiliations
Mount Sinai Hospital (CA)
Venue
Seminars in Reproductive Medicine
Published
2004-02
Volume
22
Issue
1
Pages
61-78
ISSN
  • 1526-4564 (ISSN-L)
  • 1526-8004
OpenAlex
W2401840272
Cited by
87
References
91
Citations by year
2025: 3 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 1 · 2020: 2 · 2019: 1 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 4 · 2012: 3
FWCI
7.52
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Reproductive Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
Keywords
aromatase inhibitors, ovulation induction, anovulatory infertility, clomiphene citrate, controlled ovarian stimulation, recombinant FSH, pregnancy rate, assisted reproduction
MeSH terms
Anovulation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Enzyme Inhibitors, Female, Follicle Stimulating Hormone, Gonadotropins, Humans, Infertility, Female, Ovulation Induction, Pregnancy, Recombinant Proteins, Pregnancy Rate, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review